



ACERUS ANNOUNCES DEPARTURE OF DR. MICHAEL BUMBY

Toronto, Canada, March 24, 2016 – Acerus Pharmaceuticals Corporation (TSX: APC) today announced that Dr. Michael Bumby, Chief Financial Officer, will be leaving the Company effective June 1, 2016 to pursue other opportunities.

“On behalf of the Company, I would like to thank Dr. Bumby for his contributions to the Company and take this opportunity to wish him the best of luck with his new endeavours,” stated Tom Rossi, President and Chief Executive Officer.

The Company has initiated a search for a successor to Dr. Bumby and will provide an update at the appropriate time.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus markets ESTRACE[®] in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO[™], a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. TEFINA[™], a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.

For more information, visit www.aceruspharma.com and follow us on [Twitter](#) and [LinkedIn](#).

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 1, 2016 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking

information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

#

Contact:

Tiana DiMichele
Director, Marketing & Communications
Acerus Pharmaceuticals Corporation
tdimichele@aceruspharma.com
(416) 679-0822